Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...
"Developer confidence in the market has diminished significantly, resulting in the sale of underperforming new developments," ...
LifeSci Capital is acting as the lead manager for the proposed offering ... with the VC funds of Roche, Pfizer, and Bristol-Myers Squibb joining Angelini Ventures and the JDRF T1D Fund in a ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
AbbVie said it was disappointed with the results of its emraclidine trial for treating schizophrenia Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing ...
Bristol-Myers Squibb's market capitalization grew by 24.6%, the highest increase among the top 20 companies in Q3 2024. The biopharmaceutical sector showed signs of recovery in the third quarter ...
Bristol Myers Squibb Company BMY touched a 52-week high of $56.8 on Nov. 6. The stock is currently trading at $54.14. This biotech giant has been having a good run for the past three months ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Bristol-Myers Squibb ... patients with diabetes by building on the success Amylin has had with its GLP-1 franchise. The acquisition of Amylin by Bristol-Myers Squibb is also a unique way for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback